MaxCyte, Inc. (MXCT)
NASDAQ: MXCT · Real-Time Price · USD
2.270
-0.010 (-0.44%)
Jul 11, 2025, 9:59 AM - Market open
MaxCyte Revenue
MaxCyte had revenue of $10.39M in the quarter ending March 31, 2025, a decrease of -8.39%. This brings the company's revenue in the last twelve months to $37.68M, down -14.48% year-over-year. In the year 2024, MaxCyte had annual revenue of $38.63M, down -6.44%.
Revenue (ttm)
$37.68M
Revenue Growth
-14.48%
P/S Ratio
6.37
Revenue / Employee
$330,482
Employees
114
Market Cap
241.57M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 38.63M | -2.66M | -6.44% |
Dec 31, 2023 | 41.29M | -2.97M | -6.72% |
Dec 31, 2022 | 44.26M | 10.37M | 30.59% |
Dec 31, 2021 | 33.89M | 7.73M | 29.52% |
Dec 31, 2020 | 26.17M | 4.55M | 21.04% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
MXCT News
- 2 days ago - MaxCyte to Report Second Quarter 2025 Financial Results on August 6, 2025 - GlobeNewsWire
- 10 days ago - PHC Announces Exclusive Distribution of MaxCyte® ExPERT™ Platform in Japan - Business Wire
- 4 weeks ago - MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies - GlobeNewsWire
- 2 months ago - MaxCyte, Inc. (MXCT) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance - GlobeNewsWire
- 3 months ago - MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025 - GlobeNewsWire
- 4 months ago - MaxCyte: Strong Revenues, Fast-Growing Cell-Therapy Market, Very Low Share Price - Seeking Alpha
- 4 months ago - MaxCyte, Inc. (MXCT) Q4 2024 Earnings Call Transcript - Seeking Alpha